pfizer are saying there isn’t a problem at their end. Is it the delivery, storage, manpower to distribute it?
Supply issues of the Pfizer vaccine reported elsewhere in Europe:
28 December -
BioNTech-Pfizer has postponed the delivery of new batches of its coronavirus vaccine to eight European nations including Spain, the Spanish health ministry said on Monday.
The hold-up is due to a "problem in the loading and shipment process" at its plant in Belgium, the health ministry said in a statement, citing the Spanish branch of Pfizer."
www.dw.com/en/biontech-pfizer-delays-covid-vaccine-deliveries-to-8-eu-nations/a-56074466
30 December -
Three German states, including Berlin, have been forced to suspend their coronavirus vaccine campaigns for at least a week owing to shortages in doses, German media reported Wednesday. The news comes barely four days after the first vaccine was administered in Germany. ...
An order of around 30,000 doses of the BioNTech-Pfizer vaccine due to arrive by January 4 was cancelled, according to several German media outlets. The reasons for the cancellation were not immediately clear. The BioNTech pharma company, which played a key role in developing the product, is based in the German city of Mainz.
www.dw.com/en/coronavirus-german-states-say-vaccinations-delayed-due-to-shortage/a-56097728
Vaccine production target cut by half;
8 December -
According to a Pfizer spokeswoman, challenges in the company’s supply chain played a role in its decision to cut its 2020 COVID-19 vaccine production target by half.
Recently, Pfizer announced it expected to produce 50 million doses of the BNT162b2 COVID-19 vaccine candidate this year–this is half the target of 100 million doses it set earlier in 2020.
The spokeswoman said in an interview with Reuters that the scale-up of the supply chain for raw materials used in the production of the COVID-19 vaccine had taken “longer than expected” and “played a role” in the enterprise’s decision to reduce the 2020 production target. She also added that the later-than-expected results from a clinical trial also impacted the decision.
www.europeanpharmaceuticalreview.com/news/135830/supply-chain-challenges-cause-pfizers-covid-19-vaccine-production-target-to-be-slashed/